https://www.selleckchem.com/pr....oducts/fph1-brd-6125
Objectives A phase III, 24-weeks Chinese clinical trial demonstrated that efficacy and safety outcomes of treatments with 40 mg/0.8 ml HS016 (n = 416) or adalimumab (n = 232) for active ankylosing spondylitis (AS) patients was comparable. In the present study, a subanalysis of the clinical trial was conducted to determine whether also individual efficacy indicators were comparable between HS016 and adalimumab. Methods The individual efficacy indicators total and nocturnal back pain, global assessment of disease activity, swollen j
Like
Comment
Share
